Company Overview

Checkpoint Therapeutics is committed to advancing the development of cancer immunotherapy and targeted oncology treatments and creating accessible, effective and potentially more affordable options for patients everywhere.

Along with our leading candidates cosibelimab and olafertinib, we are dedicated to developing and bringing cancer therapies to market faster and actively pursuing product purchases, in-licensing and co-development opportunities that align with our areas of expertise, offering better patient outcomes and delivering significant value to the future of healthcare.

Stock Information

Latest Financial Results

Q3 2023

Quarter Ended September 30, 2023

Latest Annual Filing

For Fiscal Year Ending December 31, 2022

IR Contacts


Checkpoint Therapeutics, Inc.
95 Sawyer Road
Suite 110
Waltham, MA 02453
T: 781-652-4500
F: 646-619-4950

Investor Relations

LifeSci Advisors, LLC
Ashley R. Robinson
Managing Director
T: 617-430-7577

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436